Literature DB >> 15352995

Effects of anagrelide on platelet factor 4 and vascular endothelial growth factor levels in patients with essential thrombocythemia.

Rossella R Cacciola, Ernesto Di Francesco, Rosario Giustolisi, Emma Cacciola.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15352995     DOI： 10.1111/j.1365-2141.2004.05139.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  3 in total

Review 1.  Anagrelide: a review of its use in the management of essential thrombocythaemia.

Authors:  Antona J Wagstaff; Gillian M Keating
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms.

Authors:  Yasuhiro Taniguchi; Hirokazu Tanaka; Espinoza J Luis; Kazuko Sakai; Takahiro Kumode; Keigo Sano; Kentarou Serizawa; Shinya Rai; Yasuyoshi Morita; Hitoshi Hanamoto; Kazuo Tsubaki; Kazuto Nishio; Itaru Matsumura
Journal:  Int J Hematol       Date:  2017-08-05       Impact factor: 2.490

3.  Percutaneous coronary intervention in a patient with heparin resistance due to essential thrombocythaemia: a case report.

Authors:  Toshitaka Okabe; Tadayuki Yakushiji; Naoei Isomura; Masahiko Ochiai
Journal:  Eur Heart J Case Rep       Date:  2021-03-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.